BUZZ - Moderna’s market value surges above $100 billion ahead of quarterly earnings release

November 4 - ** ModernaMRNA.O shares rose 10.2% to $251.67

** Based on the current share price, Moderna's market capitalization surpassed the $100 billion threshold, up by about $8 billion compared to the previous session's closing value

** Late-stage clinical data released last month showed that the vaccine "Intismeran," jointly developed by Moderna and Merck MRK.N (link), when used in combination with Merck's "Keytruda," reduced the risk of death or recurrence from melanoma by 42%, and reduced the risk of cancer spreading by 38%, compared to using "Keytruda" alone

** Moderna is scheduled to release its third-quarter earnings report on Friday, with investors expected to focus on vaccine collaboration revenues and the latest developments of this cancer vaccine

** The current trading price is about 1% lower than the intraday record high of $254.48 reached last month

** Including today's fluctuations, MRNA has surged more than eightfold so far this year

(To assist non-native English speakers, Reuters has automatically translated its reports into several other languages. As automated translation may contain errors or may not provide the desired context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation feature.)